Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Lutikizumab in Moderate to Severe Hidradenitis Suppurativa
jRCT2041240080Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Aug 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing Lutikizumab with Placebo then Lutikizumab (2 arms). Primary endpoints: HiSCR 75 at Week 16 and Adverse events up to Week 62. Started Aug 2024; status: active, not recruiting.
02
Drugs
lutikizumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on jRCT2041240080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041240080.